Remove Genetic Analysis Remove Genetic Disease Remove Marketing
article thumbnail

Agena Bioscience Granted EUA for High-Throughput, Low-Cost SARS-CoV-2 Panel

The Pharma Data

“The MassARRAY SARS-CoV-2 Panel is the only assay on the market with 5 viral genome targets multiplexed into a single reaction, making it robust against potential mutations arising in the viral genome,” said Dr. Darryl Irwin , Vice President of Scientific Affairs.

article thumbnail

Top 10 Biotech Trends for 2025

XTalks

Additionally, CRISPR genome-wide screening holds great potential for identifying key disease-associated genes and uncovering novel therapeutic targets. Furthermore, CRISPR/Cas9 presents a promising avenue for overcoming genetic diseases in the near future. The global market for cell and gene therapies , valued at $5.9